Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. / Rasmussen, Peter Vibe; Dalgaard, Frederik; Gislason, Gunnar Hilmar; Brandes, Axel; Johnsen, Søren Paaske; Grove, Erik Lerkevang; Torp-Pedersen, Christian; Münster, Anne-Marie Bloch; Erikson, Marie Schmidt; Pallisgaard, Jannik Langtved; Blanche, Paul; Hansen, Morten Lock.

In: European heart journal. Cardiovascular pharmacotherapy, Vol. 7, No. 5, 2021, p. 373–379.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rasmussen, PV, Dalgaard, F, Gislason, GH, Brandes, A, Johnsen, SP, Grove, EL, Torp-Pedersen, C, Münster, A-MB, Erikson, MS, Pallisgaard, JL, Blanche, P & Hansen, ML 2021, 'Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants', European heart journal. Cardiovascular pharmacotherapy, vol. 7, no. 5, pp. 373–379. https://doi.org/10.1093/ehjcvp/pvaa045

APA

Rasmussen, P. V., Dalgaard, F., Gislason, G. H., Brandes, A., Johnsen, S. P., Grove, E. L., Torp-Pedersen, C., Münster, A-M. B., Erikson, M. S., Pallisgaard, J. L., Blanche, P., & Hansen, M. L. (2021). Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. European heart journal. Cardiovascular pharmacotherapy, 7(5), 373–379. https://doi.org/10.1093/ehjcvp/pvaa045

Vancouver

Rasmussen PV, Dalgaard F, Gislason GH, Brandes A, Johnsen SP, Grove EL et al. Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. European heart journal. Cardiovascular pharmacotherapy. 2021;7(5):373–379. https://doi.org/10.1093/ehjcvp/pvaa045

Author

Rasmussen, Peter Vibe ; Dalgaard, Frederik ; Gislason, Gunnar Hilmar ; Brandes, Axel ; Johnsen, Søren Paaske ; Grove, Erik Lerkevang ; Torp-Pedersen, Christian ; Münster, Anne-Marie Bloch ; Erikson, Marie Schmidt ; Pallisgaard, Jannik Langtved ; Blanche, Paul ; Hansen, Morten Lock. / Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. In: European heart journal. Cardiovascular pharmacotherapy. 2021 ; Vol. 7, No. 5. pp. 373–379.

Bibtex

@article{2aa36e51361942429f65cbf100985cec,

title = "Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants",

abstract = "AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulants (OAC) have an increased risk of bleeding including hematuria. In the general population gross hematuria is associated with urinary tract cancer. Consequently, we aimed to investigate the potential association between gross hematuria and urinary tract cancer in anticoagulated patients with AF.METHODS AND RESULTS: Using Danish nationwide registers, we included Danish AF patients treated with OACs between 2001 and 2016. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risk of urinary tract cancer in patients with- and without gross hematuria. We included 125,063 AF patients with a median age of 74 years (interquartile range [IQR] 65-80) and a majority of males (57%). The absolute risk of gross hematuria 12 months after treatment initiation increased with age ranging from 0.37% (95% Confidence Interval [CI] 0.31 - 0.42) to 0.85% (95% CI 0.75 - 0.96) in the youngest and oldest age groups of ≤ 70 years and > 80 years of age, respectively. The 1-year risk of urinary tract cancer after hematuria ranged from 4.2% (95% CI 2.6-6.6) to 6.5% (95% CI 4.6-9.0) for patients in age group > 80 years and 71-80 years, respectively. Gross hematuria conferred large risk ratios of urinary tract cancer when comparing patients with- and without hematuria across all age groups.CONCLUSION: Gross hematuria was associated with clinically relevant risks of urinary tract cancer in anticoagulated patients with AF. Thus, underlining the importance of meticulously examining anticoagulated patients with hematuria.",

author = "Rasmussen, {Peter Vibe} and Frederik Dalgaard and Gislason, {Gunnar Hilmar} and Axel Brandes and Johnsen, {S{\o}ren Paaske} and Grove, {Erik Lerkevang} and Christian Torp-Pedersen and M{\"u}nster, {Anne-Marie Bloch} and Erikson, {Marie Schmidt} and Pallisgaard, {Jannik Langtved} and Paul Blanche and Hansen, {Morten Lock}",

note = "{\textcopyright} Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author 2020. For permissions, please email: journals.permissions@oup.com.",

year = "2021",

doi = "10.1093/ehjcvp/pvaa045",

language = "English",

volume = "7",

pages = "373–379",

journal = "European Heart Journal - Cardiovascular Pharmacotherapy",

issn = "2055-6837",

publisher = "Oxford University Press",

number = "5",

}

RIS

TY - JOUR

T1 - Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants

AU - Rasmussen, Peter Vibe

AU - Dalgaard, Frederik

AU - Gislason, Gunnar Hilmar

AU - Brandes, Axel

AU - Johnsen, Søren Paaske

AU - Grove, Erik Lerkevang

AU - Torp-Pedersen, Christian

AU - Münster, Anne-Marie Bloch

AU - Erikson, Marie Schmidt

AU - Pallisgaard, Jannik Langtved

AU - Blanche, Paul

AU - Hansen, Morten Lock

PY - 2021

Y1 - 2021

N2 - AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulants (OAC) have an increased risk of bleeding including hematuria. In the general population gross hematuria is associated with urinary tract cancer. Consequently, we aimed to investigate the potential association between gross hematuria and urinary tract cancer in anticoagulated patients with AF.METHODS AND RESULTS: Using Danish nationwide registers, we included Danish AF patients treated with OACs between 2001 and 2016. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risk of urinary tract cancer in patients with- and without gross hematuria. We included 125,063 AF patients with a median age of 74 years (interquartile range [IQR] 65-80) and a majority of males (57%). The absolute risk of gross hematuria 12 months after treatment initiation increased with age ranging from 0.37% (95% Confidence Interval [CI] 0.31 - 0.42) to 0.85% (95% CI 0.75 - 0.96) in the youngest and oldest age groups of ≤ 70 years and > 80 years of age, respectively. The 1-year risk of urinary tract cancer after hematuria ranged from 4.2% (95% CI 2.6-6.6) to 6.5% (95% CI 4.6-9.0) for patients in age group > 80 years and 71-80 years, respectively. Gross hematuria conferred large risk ratios of urinary tract cancer when comparing patients with- and without hematuria across all age groups.CONCLUSION: Gross hematuria was associated with clinically relevant risks of urinary tract cancer in anticoagulated patients with AF. Thus, underlining the importance of meticulously examining anticoagulated patients with hematuria.

AB - AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulants (OAC) have an increased risk of bleeding including hematuria. In the general population gross hematuria is associated with urinary tract cancer. Consequently, we aimed to investigate the potential association between gross hematuria and urinary tract cancer in anticoagulated patients with AF.METHODS AND RESULTS: Using Danish nationwide registers, we included Danish AF patients treated with OACs between 2001 and 2016. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risk of urinary tract cancer in patients with- and without gross hematuria. We included 125,063 AF patients with a median age of 74 years (interquartile range [IQR] 65-80) and a majority of males (57%). The absolute risk of gross hematuria 12 months after treatment initiation increased with age ranging from 0.37% (95% Confidence Interval [CI] 0.31 - 0.42) to 0.85% (95% CI 0.75 - 0.96) in the youngest and oldest age groups of ≤ 70 years and > 80 years of age, respectively. The 1-year risk of urinary tract cancer after hematuria ranged from 4.2% (95% CI 2.6-6.6) to 6.5% (95% CI 4.6-9.0) for patients in age group > 80 years and 71-80 years, respectively. Gross hematuria conferred large risk ratios of urinary tract cancer when comparing patients with- and without hematuria across all age groups.CONCLUSION: Gross hematuria was associated with clinically relevant risks of urinary tract cancer in anticoagulated patients with AF. Thus, underlining the importance of meticulously examining anticoagulated patients with hematuria.

U2 - 10.1093/ehjcvp/pvaa045

DO - 10.1093/ehjcvp/pvaa045

M3 - Journal article

C2 - 32369580

VL - 7

SP - 373

EP - 379

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 5

ER -

ID: 258282033

Faculty of Law